Relmada Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Relmada Therapeutics Stock Summary

Relmada Therapeutics competes with Cytokinetics, Edgewise Therapeutics, Dyne Therapeutics, Third Harmonic, and Pmv Pharmaceuticals. Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Relmada Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Relmada Therapeutics Key Financial Ratios

Relmada Therapeutics Key Balance Sheet Accounts

Relmada Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Relmada Therapeutics's current stock value. Our valuation model uses many indicators to compare Relmada Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Relmada Therapeutics competition to find correlations between indicators driving Relmada Therapeutics's intrinsic value. More Info.Relmada Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Relmada Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Relmada Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Relmada Therapeutics Systematic Risk

Today, most investors in Relmada Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Relmada Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Relmada Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Relmada Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Relmada Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Relmada Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Relmada Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Relmada Therapeutics's daily price indicators and compare them against related drivers.

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.